PubRank

Pablo Sarobe

Author PubWeight™ 40.93‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol 2013 2.63
2 Depletion of dendritic cells delays ovarian cancer progression by boosting antitumor immunity. Cancer Res 2008 1.92
3 Trial of complete weaning from immunosuppression for liver transplant recipients: factors predictive of tolerance. Liver Transpl 2013 1.66
4 CD4+/CD25+ regulatory cells inhibit activation of tumor-primed CD4+ T cells with IFN-gamma-dependent antiangiogenic activity, as well as long-lasting tumor immunity elicited by peptide vaccination. J Immunol 2003 1.61
5 Dysregulation of interferon regulatory factors impairs the expression of immunostimulatory molecules in hepatitis C virus genotype 1-infected hepatocytes. Gut 2013 1.50
6 Enhanced T cell responses against hepatitis C virus by ex vivo targeting of adenoviral particles to dendritic cells. Hepatology 2011 1.44
7 Upregulation of indoleamine 2,3-dioxygenase in hepatitis C virus infection. J Virol 2007 1.29
8 The extra domain A from fibronectin targets antigens to TLR4-expressing cells and induces cytotoxic T cell responses in vivo. J Immunol 2007 1.08
9 A synthetic peptide from transforming growth factor-beta1 type III receptor prevents myocardial fibrosis in spontaneously hypertensive rats. Cardiovasc Res 2008 1.07
10 Adjuvant combination and antigen targeting as a strategy to induce polyfunctional and high-avidity T-cell responses against poorly immunogenic tumors. Cancer Res 2011 1.06
11 A peptide inhibitor of FOXP3 impairs regulatory T cell activity and improves vaccine efficacy in mice. J Immunol 2010 1.03
12 Identification of peptide inhibitors of transforming growth factor beta 1 using a phage-displayed peptide library. Cytokine 2007 1.01
13 Identification of an antigenic epitope for helper T lymphocytes from carcinoembryonic antigen. Clin Cancer Res 2002 1.01
14 In vitro and in vivo down-regulation of regulatory T cell activity with a peptide inhibitor of TGF-beta1. J Immunol 2008 0.98
15 Induction of monocyte chemoattractant protein-1 and interleukin-10 by TGFbeta1 in melanoma enhances tumor infiltration and immunosuppression. Cancer Res 2010 0.97
16 Vaccination with an adenoviral vector encoding hepatitis C virus (HCV) NS3 protein protects against infection with HCV-recombinant vaccinia virus. Vaccine 2002 0.96
17 Peptide inhibitors of transforming growth factor-beta enhance the efficacy of antitumor immunotherapy. Int J Cancer 2009 0.92
18 Is plasma cardiotrophin-1 a marker of hypertensive heart disease? J Hypertens 2005 0.91
19 Hepatitis C virus induces the expression of CCL17 and CCL22 chemokines that attract regulatory T cells to the site of infection. J Hepatol 2010 0.91
20 The combined actions of NK and T lymphocytes are necessary to reject an EGFP+ mesenchymal tumor through mechanisms dependent on NKG2D and IFN gamma. Int J Cancer 2007 0.90
21 Improved dendritic cell-based immunization against hepatitis C virus using peptide inhibitors of interleukin 10. Hepatology 2010 0.89
22 Therapeutic effect of a peptide inhibitor of TGF-β on pulmonary fibrosis. Cytokine 2010 0.89
23 Vaccination against hepatitis C virus with dendritic cells transduced with an adenovirus encoding NS3 protein. Mol Ther 2007 0.88
24 Enhancing immunogenicity of a CTL epitope from carcinoembryonic antigen by selective amino acid replacements. Clin Cancer Res 2002 0.87
25 Combined immunization with adjuvant molecules poly(I:C) and anti-CD40 plus a tumor antigen has potent prophylactic and therapeutic antitumor effects. Cancer Immunol Immunother 2007 0.87
26 Oncostatin M enhances the antiviral effects of type I interferon and activates immunostimulatory functions in liver epithelial cells. J Virol 2009 0.87
27 Eradication of large tumors expressing human papillomavirus E7 protein by therapeutic vaccination with E7 fused to the extra domain a from fibronectin. Int J Cancer 2011 0.85
28 Immunization against hepatitis C virus with a fusion protein containing the extra domain A from fibronectin and the hepatitis C virus NS3 protein. J Hepatol 2009 0.84
29 A recombinant adenovirus encoding hepatitis C virus core and E1 proteins protects mice against cytokine-induced liver damage. Hepatology 2003 0.83
30 Enhancement of CD4 and CD8 immunity by anti-CD137 (4-1BB) monoclonal antibodies during hepatitis C vaccination with recombinant adenovirus. Vaccine 2005 0.82
31 Epitope enhancement of a CD4 HIV epitope toward the development of the next generation HIV vaccine. J Immunol 2006 0.81
32 A fusion protein between streptavidin and the endogenous TLR4 ligand EDA targets biotinylated antigens to dendritic cells and induces T cell responses in vivo. Biomed Res Int 2013 0.81
33 Identification and characterization of a T-helper peptide from carcinoembryonic antigen. Clin Cancer Res 2004 0.80
34 Combination of a TLR4 ligand and anaphylatoxin C5a for the induction of antigen-specific cytotoxic T cell responses. Vaccine 2012 0.79
35 Induction of potent and long-lasting CD4 and CD8 T-cell responses against hepatitis C virus by immunization with viral antigens plus poly(I:C) and anti-CD40. Antiviral Res 2007 0.78
36 Low molecular weight hyaluronan preconditioning of tumor-pulsed dendritic cells increases their migratory ability and induces immunity against murine colorectal carcinoma. Cancer Immunol Immunother 2011 0.78
37 Radioembolization of hepatocellular carcinoma activates liver regeneration, induces inflammation and endothelial stress and activates coagulation. Liver Int 2014 0.77
38 The epidermal growth factor receptor ligand amphiregulin is a negative regulator of hepatic acute-phase gene expression. J Hepatol 2009 0.77
39 MAGE antigens: therapeutic targets in hepatocellular carcinoma? J Hepatol 2004 0.75
40 Tumor therapy in mice by using a tumor antigen linked to modulin peptides from Staphylococcus epidermidis. Vaccine 2010 0.75
41 Engineered promiscuous T helper peptides for the induction of immune responses. Mol Immunol 2006 0.75
42 International symposium on CTL and immunostimulation, Pamplona (Spain), October 26th and 27th 2010. Cancer Immunol Immunother 2011 0.75
43 Identification of HLA-B27-restricted cytotoxic T lymphocyte epitope from carcinoembryonic antigen. Int J Cancer 2002 0.75
44 [New therapies for hepatitis C]. Med Clin (Barc) 2006 0.75
45 Engineering Th determinants for efficient priming of humoral and cytotoxic T cell responses. Int Immunol 2003 0.75